HC Wainwright Has Weak Outlook for InflaRx FY2024 Earnings

InflaRx (NASDAQ:IFRX) – Equities research analysts at HC Wainwright dropped their FY2024 earnings per share estimates for InflaRx in a research report issued on Monday, November 11th. HC Wainwright analyst E. White now anticipates that the company will post earnings of ($1.05) per share for the year, down from their prior forecast of ($0.97). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for InflaRx’s current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for InflaRx’s Q4 2024 earnings at ($0.31) EPS, FY2025 earnings at ($1.16) EPS and FY2026 earnings at ($1.13) EPS.

InflaRx Stock Performance

InflaRx stock opened at $2.03 on Thursday. The firm has a market cap of $119.53 million, a price-to-earnings ratio of -1.88 and a beta of 1.57. InflaRx has a 52-week low of $1.17 and a 52-week high of $2.44. The firm has a 50 day moving average price of $1.53 and a two-hundred day moving average price of $1.51.

Hedge Funds Weigh In On InflaRx

A hedge fund recently raised its stake in InflaRx stock. Ikarian Capital LLC grew its holdings in shares of InflaRx (NASDAQ:IFRX) by 2.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 704,987 shares of the company’s stock after acquiring an additional 16,383 shares during the period. Ikarian Capital LLC owned 1.20% of InflaRx worth $1,086,000 as of its most recent SEC filing. 42.39% of the stock is owned by institutional investors.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.